|
| Observation on clinical effects of Xueshuantong Injection combined with recombinant human brain natriuretic peptide in patients with acute ST-segment elevation myocardial infarction after emergency PCI |
| Hits 524 Download times 278 Received:August 02, 2022 |
| View Full Text View/Add Comment Download reader |
| DOI
10.11656/j.issn.1672-1519.2022.11.03 |
| Key Words
Xueshuantong Injection;recombinant human brain natriuretic peptide;acute ST-segment elevation myocardial infarction;hemodynamics;myocardial injury markers |
| Author Name | Affiliation | E-mail | | YANG Wei | Department of Emergency, Rugao Hospital Affiliated to Nantong University &
Rugao People's Hospital of Jiangsu Province, Rugao 226500, China | | | LIU Huihui | Department of Cardiovascular, Rugao Hospital Affiliated to Nantong University &
Rugao People's Hospital of Jiangsu Province, Rugao 226500, China | | | CHEN Juan | Department of Emergency, Rugao Hospital Affiliated to Nantong University &
Rugao People's Hospital of Jiangsu Province, Rugao 226500, China | | | HUANG Yanhua | Department of Emergency, Rugao Hospital Affiliated to Nantong University &
Rugao People's Hospital of Jiangsu Province, Rugao 226500, China | 1482129426@qq.com |
|
| Abstract
|
| [Objective] To explore the clinical efficacy of Xueshuantong Injection combined with recombinant human brain natriuretic peptide(rhBNP) in patients with acute ST-segment elevation myocardial infarction(STEMI) after emergency percutaneous coronary intervention (PCI).[Methods] The 110 STEMI patients who underwent emergency PCI treatment in hospital from January 2019 to May 2021 were selected as research objects,and divided into observation group and control group with 55 cases each randomly. After emergency PCI,on the basis of routine treatment,the observation group was treated with Xueshuantong Injection combined with rhBNP, and the control group was treated with rhBNP alone. Measured two groups' cardiac ultrasound indexes[left ventricular end diastolic volume and left ventricular end systolic volume(LVEDV and LVESV),left ventricular ejection fraction(LVEF)],hemodynamic parameters[cardiac output (CO),left ventricular stroke work (LSW),mean arterial pressure (MAP),as well as serum N-terminal B-type natriuretic peptide (NT-proBNP),growth differentiation factor 15 (GDF-15),soluble suppression of tumorigenicity 2 (sST2) and galectin 3 (Gal-3) levels before and after treatment. Occurrence of major adverse cardiac events (MACE) within 6 months after PCI was counted. And the side effects of the two groups were compared.[Results] After treatment,LVEDV and LVESV in the two groups were significantly decreased compared with before treatment (P<0.05),and LVEF was significantly increased compared with before treatment (P<0.05). LVEDV, LVESV and LVEF in observation group were significantly better than those in control group (P<0.05). After treatment,CO and LSW and MAP in the two groups were significantly increased compared with before treatment(P<0.05). CO,LSW and MAP in observation group were significantly higher than those in control group(P<0.05). After treatment,the serum concentrations of GDF-15,sST2,Gal-3 and NT-proBNP in the two groups were significantly decreased compared with before treatment (P<0.05). The serum levels of GDF-15,sST2,Gal-3 and NT-proBNP in the observation group were significantly lower than those in the control group (P<0.05). Within 6 months of follow-up after PCI,the incidence of MACE in observation group was 5.45%(3/55),which was significant lower than that in control group[18.18% (10/55),P<0.05]. The adverse reaction rate of observation group was 12.73%(7/55),which was no statistical different from that of the control group[9.09%(5/55),P>0.05].[Conclusion] Xueshuantong Injection combined with rhBNP treatment can effectively down-regulate the serum NT-proBNP,GDF-15,sST2 and Gal-3 expression levels in STEMI patients after emergency PCI,and improve after post-PCI hemodynamics and cardiac function,and reduce postoperative MACE with good safety. |
|
|
|
|
|
|
|
